Pinealon (Glu-Asp-Arg)

The upside is concentrated in mechanism, not in proven results, and even the mechanism is mostly single-source. Pinealon's genuine asset is a coherent laboratory story: it restricts oxidative stress in neurons and can physically contact DNA, which makes the neuroprotection idea plausible. Its weakness is that none of this has been shown to help an actual person think better, and the human file is a single uncontrolled cohort. Breadth and bioindividuality score modestly because the geroprotective lane is real but soft-endpoint. Evidence is the dimension that drags the whole thing down, and it does so for a clear reason.

Efficacy (2.0/5.0): Efficacy is low because there is no demonstrated human benefit and no human effect size anywhere. The strongest human signal is an open-label cohort of 32 polymorbid patients who reportedly improved adaptive capacity and showed slowed biological-age markers, per Meshchaninov 2015, but that study had no placebo, no blinding, and soft endpoints. Animal work is more consistent: Pinealon improved Morris-maze learning in rats more than cortexin, per Mendzheritski 2013, and rescued offspring learning in a prenatal-stress rat model, per Arutjunyan 2012. None of that reports a Cohen's d, an NNT, or a confidence interval, and cell-and-animal effects do not transfer to a human number. A coherent mechanism without a confirmed human outcome cannot score as effective for the uses people actually buy it for.

Breadth of Benefits (2.4/5.0): Breadth is modest because the claims span cognition, neuroprotection, mood, and aging, but they all sit in one neuro-geroprotective lane and all rest on soft endpoints. The mechanism touches several systems on paper: serotonin expression in cortex cells, per Khavinson 2014, oxidative-stress handling in neurons, per Khavinson 2011, and oxidative DNA damage in aged human-derived induced neurons, per Kraskovskaya 2024. The boundary is that breadth of mechanism is not breadth of proof. In humans, not one of these systems has a controlled endpoint, so the apparent range collapses to a single, thinly-supported theme.

Evidence Quality (1.8/5.0): This is the dimension that pulls the score lowest, and the reason is simple: rigorous independent human trials are essentially absent. There are zero registered studies on ClinicalTrials.gov, no FDA record, and no independent Western replication of the functional gene-regulation claims. The entire human file is a handful of small, uncontrolled, single-lab Russian cohorts, the strongest being just 32 people, per Meshchaninov 2015, plus occupational cohorts that often combined peptides, per Bashkireva 2012. The mechanism work is almost all from the originating group, and the one outside-lab contribution is purely biophysical, confirming that EDR can contact DNA, per Silanteva 2019, not that it regulates neurons in a living brain. Publication concentrated in a few institute-linked journals is a textbook single-source pattern, and it keeps this dimension near the floor.

Speed of Onset (2.8/5.0): Speed is a relative bright spot, but only at the cell level. Antioxidant and anti-apoptotic effects in cultured neurons appear quickly, per Khavinson 2011, and the human and animal protocols run as short courses, typically the published two-week oral course, per Nazimko 2012. What is missing is any characterized human onset for a cognitive effect, since no human study measures one. So the fast biochemistry is well-supported, while the fast subjective effect that users describe is anecdotal. It is worth being precise about what "fast" means here, because the marketing tends to borrow the speed of the test-tube result and quietly apply it to the brain. A peptide that changes a readout in a dish within minutes tells you nothing about how long it takes, or whether it happens at all, for an intact peptide that has to survive digestion or injection, reach the brain, and produce a change you can actually feel. With no human pharmacokinetic study to pin down that timeline, the score reflects fast laboratory chemistry sitting on top of an unknown real-world onset.

Durability (2.0/5.0): Durability is low because the protocol itself implies the effect does not last. Khavinson dosing is explicitly course-based, short pulses repeated every three to six months, which signals the originators do not expect a single durable result, per the program review by Umnov 2013. No human study reports a washout period, a follow-up duration, or any relapse data, and the animal work measured only acute-to-subacute windows. Whatever effect exists, if any, looks like something you would have to keep re-dosing to maintain. This matters for how you would even think about value. A durable intervention can justify its cost and effort because you pay once and keep the benefit; a pulsed one that fades between courses is a recurring subscription. Pinealon is structured like the second kind, and the bioregulator framework leans into that on purpose, treating these peptides as periodic signals rather than one-time resets. Without any data on how long a given course holds, the honest assumption is that any benefit decays once you stop, which lowers the practical payoff further.

Bioindividuality Upside (2.4/5.0): Bioindividuality is neutral-leaning-low because there is almost no responder data to work with. The human cohorts skewed older and polymorbid, and those subjects reported improved adaptive capacity, per Meshchaninov 2015, which hints that lower-baseline older adults might notice more. But there is no biomarker predictor, no genetic stratifier, and no responder-versus-non-responder breakdown anywhere. With samples this small and uncontrolled, any apparent individual variation is as likely to be noise as a real modifier, so the score stays modest.